These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 10414917

  • 1. A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation.
    Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K.
    Bone Marrow Transplant; 1999 Jun; 23(12):1283-9. PubMed ID: 10414917
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice.
    Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ebata T, Wada Y, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K.
    Blood; 1997 Jul 15; 90(2):542-8. PubMed ID: 9226153
    [Abstract] [Full Text] [Related]

  • 5. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.
    Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S.
    Cancer Res; 1999 Mar 15; 59(6):1252-8. PubMed ID: 10096556
    [Abstract] [Full Text] [Related]

  • 6. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug 15; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB, Elkin G, Khitrin S, Slavin S.
    Exp Hematol; 2008 Dec 15; 36(12):1750-9. PubMed ID: 18809241
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.
    Nagler A, Ohana M, Alper R, Doviner V, Sherman Y, Rabbani E, Engelhardt D, Ilan Y.
    Bone Marrow Transplant; 2003 Aug 15; 32(4):363-9. PubMed ID: 12900772
    [Abstract] [Full Text] [Related]

  • 11. A two-phase pathogenesis of graft-versus-host disease in mice.
    van Leeuwen L, Guiffre A, Atkinson K, Rainer SP, Sewell WA.
    Bone Marrow Transplant; 2002 Jan 15; 29(2):151-8. PubMed ID: 11850710
    [Abstract] [Full Text] [Related]

  • 12. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW, Bohana-Kashtan O, Civin CI.
    Transplantation; 2006 Aug 27; 82(4):471-8. PubMed ID: 16926590
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.
    Nat Med; 2003 Sep 27; 9(9):1144-50. PubMed ID: 12925844
    [Abstract] [Full Text] [Related]

  • 15. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
    Leng C, Gries M, Ziegler J, Lokshin A, Mascagni P, Lentzsch S, Mapara MY.
    Exp Hematol; 2006 Jun 27; 34(6):776-87. PubMed ID: 16728283
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mixed hematopoietic chimerism for preventing graft-versus-host disease in mice receiving rat bone marrow transplantation.
    Pei FY, Li CF, Tang XF.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Jul 27; 23(7):709-13. PubMed ID: 12865228
    [Abstract] [Full Text] [Related]

  • 18. [Study of experimental mixed bone marrow transplantation].
    Luo H, Yang P, He F.
    Zhonghua Xue Ye Xue Za Zhi; 1998 Aug 27; 19(8):418-21. PubMed ID: 11189509
    [Abstract] [Full Text] [Related]

  • 19. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM, Waller EK.
    Biol Blood Marrow Transplant; 2004 Aug 27; 10(8):540-51. PubMed ID: 15282532
    [Abstract] [Full Text] [Related]

  • 20. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y, Yoshihara S, Hoshida Y, Inoue T, Fujioka T, Ikegame K, Kawakami M, Masuda T, Aozasa K, Kawase I, Ogawa H.
    Exp Hematol; 2008 Sep 27; 36(9):1216-25. PubMed ID: 18599183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.